31 related articles for article (PubMed ID: 35533722)
1. Microenvironment-dependent growth of Sezary cells in humanized IL-15 mice.
Gao J; Ren S; Choonoo G; Chen G; Frleta D; Zhong J; Gupta N; Sharma P; Oyejide A; Atwal GS; Macdonald L; Murphy A; Kuhnert F
Dis Model Mech; 2023 Oct; 16(10):. PubMed ID: 37718909
[TBL] [Abstract][Full Text] [Related]
2. IL-4 prevents adenosine-mediated immunoregulation by inhibiting CD39 expression.
Fang F; Cao W; Mu Y; Okuyama H; Li L; Qiu J; Weyand CM; Goronzy JJ
JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35730568
[TBL] [Abstract][Full Text] [Related]
3. CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker.
Li C; Zhang L; Jin Q; Jiang H; Wu C
Biomark Med; 2023 Jun; 17(12):563-576. PubMed ID: 37713234
[TBL] [Abstract][Full Text] [Related]
4. CD39 is expressed by a wide range of cutaneous T-cell lymphomas.
Battesti G; Thonnart N; Bozonnat A; Ram-Wolff C; de Masson A; Bensussan A; Bagot M; Marie-Cardine A; Battistella M
Skin Health Dis; 2024 Apr; 4(2):e334. PubMed ID: 38577051
[TBL] [Abstract][Full Text] [Related]
5. Role of cytokine in malignant T-cell metabolism and subsequent alternation in T-cell tumor microenvironment.
Yadav M; Uikey BN; Rathore SS; Gupta P; Kashyap D; Kumar C; Shukla D; Vijayamahantesh ; Chandel AS; Ahirwar B; Singh AK; Suman SS; Priyadarshi A; Amit A
Front Oncol; 2023; 13():1235711. PubMed ID: 37746258
[TBL] [Abstract][Full Text] [Related]
6. Combined High-Throughput Approaches Reveal the Signals Driven by Skin and Blood Environments and Define the Tumor Heterogeneity in Sézary Syndrome.
Cristofoletti C; Bresin A; Fioretti M; Russo G; Narducci MG
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740513
[TBL] [Abstract][Full Text] [Related]
7. Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome.
Moerman-Herzog A; Mehdi SJ; Wong HK
Cells; 2020 Aug; 9(9):. PubMed ID: 32872487
[TBL] [Abstract][Full Text] [Related]
8. The abnormal function of CD39
Lu Y; Cheng L; Li F; Ji L; Shao X; Wu B; Zhan Y; Liu C; Min Z; Ke Y; Sun L; Chen H; Cheng Y
Ann Hematol; 2019 Aug; 98(8):1845-1854. PubMed ID: 31154474
[TBL] [Abstract][Full Text] [Related]
9. CD39/CD73 dysregulation and adenosine metabolism contribute to T-cell immunosuppression in patients with Sézary syndrome.
Yakymiv Y; Marchisio S; Ortolan E; Bracci C; Senetta R; Rumore MR; Tampieri C; Fia M; Ribero S; Funaro A; Quaglino P
Blood; 2023 Jan; 141(1):111-116. PubMed ID: 36040496
[No Abstract] [Full Text] [Related]
10. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
[TBL] [Abstract][Full Text] [Related]
11. A single-nucleotide polymorphism in the human ENTPD1 gene encoding CD39 is associated with worsened graft-versus-host disease in a humanized mouse model.
Adhikary SR; Cuthbertson P; Turner RJ; Sluyter R; Watson D
Immunol Cell Biol; 2020 May; 98(5):397-410. PubMed ID: 32181525
[TBL] [Abstract][Full Text] [Related]
12. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.
Hilchey SP; Kobie JJ; Cochran MR; Secor-Socha S; Wang JC; Hyrien O; Burack WR; Mosmann TR; Quataert SA; Bernstein SH
J Immunol; 2009 Nov; 183(10):6157-66. PubMed ID: 19864600
[TBL] [Abstract][Full Text] [Related]
13. Genetically Driven CD39 Expression Affects Sezary Cell Viability and IL-2 Production and Detects Two Patient Subsets with Distinct Prognosis.
Picozza M; Cristofoletti C; Bresin A; Fioretti M; Sambucci M; Scala E; Monopoli A; Cantonetti M; Pilla MA; Accetturi MP; Borsellino G; D'Atri S; Caprini E; Russo G; Narducci MG
J Invest Dermatol; 2022 Nov; 142(11):3009-3019.e9. PubMed ID: 35533722
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
